The FDA has granted fast track designation to Amylyx's experimental therapy AMX0114 for the treatment of amyotrophic lateral ...

The FDA has granted fast-track designation to an investigational antisense oligonucleotide that targets a specific driver of ...

A phase 1 trial, LUMINA, is currently underway and is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMX0114 in approximately 48 patients with ALS.

Amylyx Pharmaceuticals (NASDAQ:AMLX) said on Tuesday that the U.S. FDA has granted fast track status to its antisense RNA, ...

Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis ...

Department of Animal Sciences, University of Florida, Gainesville, FL, United States Autogenous proteolytic enzymes of the calpain family are implicated in myofibrillar protein degradation. As a ...

[26–28] They found calpain 3 was not detected by western blotting, which is probably due to its degradation by nonsense-mediated mRNA decay. Three patients harbored two null alleles, and were ...

The late stages of muscle development turn out to be driven by a protein-degradation process that is usually associated with unhealthy cellular stress Figure 1: A scanning electron micrograph of a ...

AMX0114 is designed to target calpain-2, a calcium-dependent protease known to play a role in several neurodegenerative diseases. “Based on several preclinical efficacy studies and what is known ...

We previously showed that the ESCRT-III subunit IST1 binds the cysteine protease Calpain-7 (CAPN7) and that CAPN7 is required for both efficient abscission and NoCut checkpoint maintenance (Wenzel et ...